GSEP
IRMD icon

Golden State Equity Partners’s iRadimed IRMD Stock Holding History

Golden State Equity Partners’s Portfolio IRMD Stock Details IRMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-28
Closed -$2.69K – 1020
2026
Q1 		$2.69K Buy
+28
New +$2.8K ﹤0.01% 1606

Other funds holding IRMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
CCM
Copeland Capital Management Conshohocken, Pennsylvania $4.87B AUM 31.21% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
NTCM
Nine Ten Capital Management Chicago, Illinois $321M AUM 44.58% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Golden State Equity Partners's IRMD Position: Q2 2026 in Review

Golden State Equity Partners sold out of iRadimed (IRMD) in Q2 2026, closing a stake of 28 shares — an estimated $2.69K sold.

Golden State Equity Partners first reported a position in IRMD in Q1 2026 and held it in 1 quarter. The position peaked at $2.69K in Q1 2026. 214 funds tracked by Wall St. Rank hold IRMD as of Q2 2026.

  • Golden State Equity Partners reported no remaining iRadimed position as of Q2 2026 after selling out during the quarter.
  • Golden State Equity Partners sold 28 iRadimed shares in Q2 2026, an estimated $2.69K.
  • Golden State Equity Partners first reported a position in iRadimed in Q1 2026 and held it in 1 quarter.
  • Golden State Equity Partners's iRadimed position peaked at $2.69K in Q1 2026.
  • 214 funds tracked by Wall St. Rank held iRadimed as of Q2 2026.

Based on Golden State Equity Partners's 13F filing for Q2 2026, filed 30 Jul 2026.